Cargando…
Hepatic arterial embolization in patients with neuroendocrine tumors
Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient’s quality of life, because of either tumor bulk or hormonal hypersecretion. Therapie...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038067/ https://www.ncbi.nlm.nih.gov/pubmed/24887262 http://dx.doi.org/10.1186/1756-9966-33-43 |
_version_ | 1782318322704973824 |
---|---|
author | Del Prete, Michela Fiore, Francesco Modica, Roberta Marotta, Vincenzo Marciello, Francesca Ramundo, Valeria Di Sarno, Antonella Carratù, Annachiara di Roseto, Chiara de Luca Tafuto, Salvatore Tatangelo, Fabiana Baldelli, Robero Colao, Annamaria Faggiano, Antongiulio |
author_facet | Del Prete, Michela Fiore, Francesco Modica, Roberta Marotta, Vincenzo Marciello, Francesca Ramundo, Valeria Di Sarno, Antonella Carratù, Annachiara di Roseto, Chiara de Luca Tafuto, Salvatore Tatangelo, Fabiana Baldelli, Robero Colao, Annamaria Faggiano, Antongiulio |
author_sort | Del Prete, Michela |
collection | PubMed |
description | Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient’s quality of life, because of either tumor bulk or hormonal hypersecretion. Therapies for NEN liver metastases include surgical resection, liver transplantation, chemotherapy and biotherapy. Surgery is the gold standard for curative therapy, but in most of NEN patients with liver metastases, when surgery can not be applied, minimally invasive therapeutic approaches are adopted. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation and new emerging techniques. TAE is based on selective infusion of particles in the branch of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. Many reports have shown that TAE can reduce tumor size and hormone output, resulting in palliation of symptoms without the use of cytotoxic drugs, resulting in better tolerability. This review will focus on TAE performance and safety in NEN patients with liver metastases. |
format | Online Article Text |
id | pubmed-4038067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40380672014-05-30 Hepatic arterial embolization in patients with neuroendocrine tumors Del Prete, Michela Fiore, Francesco Modica, Roberta Marotta, Vincenzo Marciello, Francesca Ramundo, Valeria Di Sarno, Antonella Carratù, Annachiara di Roseto, Chiara de Luca Tafuto, Salvatore Tatangelo, Fabiana Baldelli, Robero Colao, Annamaria Faggiano, Antongiulio J Exp Clin Cancer Res Review Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient’s quality of life, because of either tumor bulk or hormonal hypersecretion. Therapies for NEN liver metastases include surgical resection, liver transplantation, chemotherapy and biotherapy. Surgery is the gold standard for curative therapy, but in most of NEN patients with liver metastases, when surgery can not be applied, minimally invasive therapeutic approaches are adopted. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation and new emerging techniques. TAE is based on selective infusion of particles in the branch of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. Many reports have shown that TAE can reduce tumor size and hormone output, resulting in palliation of symptoms without the use of cytotoxic drugs, resulting in better tolerability. This review will focus on TAE performance and safety in NEN patients with liver metastases. BioMed Central 2014-05-19 /pmc/articles/PMC4038067/ /pubmed/24887262 http://dx.doi.org/10.1186/1756-9966-33-43 Text en Copyright © 2014 Del Prete et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Del Prete, Michela Fiore, Francesco Modica, Roberta Marotta, Vincenzo Marciello, Francesca Ramundo, Valeria Di Sarno, Antonella Carratù, Annachiara di Roseto, Chiara de Luca Tafuto, Salvatore Tatangelo, Fabiana Baldelli, Robero Colao, Annamaria Faggiano, Antongiulio Hepatic arterial embolization in patients with neuroendocrine tumors |
title | Hepatic arterial embolization in patients with neuroendocrine tumors |
title_full | Hepatic arterial embolization in patients with neuroendocrine tumors |
title_fullStr | Hepatic arterial embolization in patients with neuroendocrine tumors |
title_full_unstemmed | Hepatic arterial embolization in patients with neuroendocrine tumors |
title_short | Hepatic arterial embolization in patients with neuroendocrine tumors |
title_sort | hepatic arterial embolization in patients with neuroendocrine tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038067/ https://www.ncbi.nlm.nih.gov/pubmed/24887262 http://dx.doi.org/10.1186/1756-9966-33-43 |
work_keys_str_mv | AT delpretemichela hepaticarterialembolizationinpatientswithneuroendocrinetumors AT fiorefrancesco hepaticarterialembolizationinpatientswithneuroendocrinetumors AT modicaroberta hepaticarterialembolizationinpatientswithneuroendocrinetumors AT marottavincenzo hepaticarterialembolizationinpatientswithneuroendocrinetumors AT marciellofrancesca hepaticarterialembolizationinpatientswithneuroendocrinetumors AT ramundovaleria hepaticarterialembolizationinpatientswithneuroendocrinetumors AT disarnoantonella hepaticarterialembolizationinpatientswithneuroendocrinetumors AT carratuannachiara hepaticarterialembolizationinpatientswithneuroendocrinetumors AT dirosetochiaradeluca hepaticarterialembolizationinpatientswithneuroendocrinetumors AT tafutosalvatore hepaticarterialembolizationinpatientswithneuroendocrinetumors AT tatangelofabiana hepaticarterialembolizationinpatientswithneuroendocrinetumors AT baldellirobero hepaticarterialembolizationinpatientswithneuroendocrinetumors AT colaoannamaria hepaticarterialembolizationinpatientswithneuroendocrinetumors AT faggianoantongiulio hepaticarterialembolizationinpatientswithneuroendocrinetumors |